Article Text

Download PDFPDF
Targeting hepatic stellate cells to combat liver fibrosis: where do we stand?
  1. Katja Breitkopf-Heinlein1,
  2. Maria Luz Martinez-Chantar2
  1. 1Department of Surgery, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Baden-Württemberg, Germany
  2. 2Liver Disease Lab, Center for Cooperative Research in Biosciences, Derio, Spain
  1. Correspondence to Dr Katja Breitkopf-Heinlein, Department of Surgery, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany; katja.breitkopf{at}medma.uni-heidelberg.de

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Liver fibrosis is characterised by the excessive deposition of extracellular matrix (ECM) in response to chronic and sustained liver damage, triggering a prolonged wound healing response. The accumulation of ECM proteins disrupts the normal hepatic architecture, resulting in the development of fibrotic scars and nodules of regenerated hepatocytes, ultimately progressing to cirrhosis. While the acute wound healing response can be transiently initiated, its progression to fibrosis requires chronic exposure to damaging agents, including viral infections, autoimmune disorders, alcohol and drug abuse, cholestatic conditions, and metabolic diseases.

Cirrhosis represents an advanced stage of liver disease characterised by distorted liver parenchyma, nodule formation, hepatic dysfunction or insufficiency and reduced intrahepatic blood flow leading to portal hypertension.1–3

Hepatic stellate cells (HSCs), also termed Ito cells, lipocytes, fat storing or perisinusoidal cells, play a pivotal role in liver fibrosis regardless of its aetiology. They act as major producers of ECM and amplify the fibrogenic response.1 2 In a healthy liver, HSCs reside in the space of Disse in between hepatocytes and liver sinusoidal endothelial cells (LSEC). On liver injury, HSCs undergo activation and differentiation into myofibroblast-like cells, a process that is characterised by proliferation, contraction, inflammation and gain of fibrogenic capabilities. Activated HSCs migrate throughout the liver and thereby accumulate in damaged areas where they are replacing injured …

View Full Text

Footnotes

  • Contributors Corresponding authors MLM-C mlmartinez@cicbiogune.es and KB-H Katja.Breitkopf@medma.uni-heidelberg.de.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles